Alnylam Pharmaceuticals
ALNY
#634
Rank
A$48.84 B
Marketcap
$378.66
Share price
-0.80%
Change (1 day)
51.74%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.06

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$6.31. In 2022 the company made an earnings per share (EPS) of -$14.25 a decrease over its 2021 EPS that were of -$11.05.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.06-57.51%
2022-$14.2529.03%
2021-$11.05-3.36%
2020-$11.43-8.48%
2019-$12.497.67%
2018-$11.6039.74%
2017-$8.3012.94%
2016-$7.3538.84%
2015-$5.29-32.88%
2014-$7.89259.44%
2013-$2.19-31.25%
2012-$3.1952.94%
2011-$2.0930.77%
2010-$1.60-8.77%
2009-$1.7578.13%
2008-$0.98-70.78%
2007-$3.3699.09%
2006-$1.69-43.88%
2005-$3.01-82.33%
2004-$17.02-59.23%
2003-$41.75

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.61-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$57.32-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$12.01 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.41-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.59-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.74-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.88-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.07-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel